João Pedro Ferrari-Souza

Aug 3, 2023 | alz-journals.onlinelibrary.wiley.com | Joseph Therriault |Cecile Tissot |João Pedro Ferrari-Souza |Andrea L. Benedet

Abstract INTRODUCTION Phosphorylated tau (p-tau) biomarkers have been recently proposed to represent brain amyloid-β (Aβ) pathology. Here, we evaluated the plasma biomarkers' contribution beyond the information provided by demographics (age and sex) to identify Aβ and tau pathologies in individuals segregated as cognitively unimpaired (CU) and impaired (CI). METHODS We assessed 138 CU and 87 CI with available plasma p-tau231, 217+, and 181, Aβ42/40, GFAP and Aβ- and tau-PET.